Central Laboratories Featured Articles

1. Where Are We With Clinical Trial Tokenization? 6/19/2026

   In January 2024, I interviewed Tom Dougherty about a topic many clinical research professionals had heard mentioned but few could confidently explain: tokenization. I wanted to get caught up on any progress that has been made, so I completed this Q&A with Dougherty, who is Real-World Data Strategy Director, CMR - Clinical Data Science & Evidence at Novo Nordisk.

2. The Compliance Problem With Excel Trackers And Other Computational Tools — And How AI Can Help 6/16/2026

   Everyday computational tools such as Excel are simple and easy to use, but they carry risk. Learn how these tools might not adhere to 21 CFR Part 11, and discover how AI can help keep them compliant.

3. It's A Fact: Sharing Clinical Trial Results With Participants Builds Trust 5/14/2026

   CISCRP experts share results from their annual Perceptions & Insights Study showing that patients continue to place a high value on receiving both individual and overall study results.

4. Reimagining Data Governance For The AI Era 4/24/2026

   Understand the persistent governance challenges that undermine AI initiatives and walk away with a robust blueprint for building a resilient, scalable, and ethically sound framework.

5. Is It Time To Replace RECIST — Or Just Add AI? 4/16/2026

   Immunocore Chief Regulatory and Quality Officer Mark Moyer explains why new tools, including AI-based approaches, may better capture cancer treatment response than existing measures, such as ir-RECIST.

6. RBQM And Centralized Monitoring Need Action 4/10/2026

   After COVID forced sponsors to move faster than ever, many are now confronting a harder challenge: ownership. Marci Thear explains why RBQM and centralized monitoring only work when sponsors move beyond reviewing outputs and start acting on the signals.

7. Redefining Patient Outcomes Measurement Using RWE Data 4/7/2026

   Discover an outcome-channeling framework that organizes patient outcomes into multidimensional domains, emphasing longitudinal trajectories rather than single time endpoints.

8. RWD Helps Researchers Include More Patients In Lymphoma Research 4/2/2026

   Andrew Evens, DO, MBA, explores how outcomes research and collaboration across academic networks, registries, and industry partners are advancing more inclusive, data-informed approaches to lymphoma research.

9. Unlocking Biopharma Innovation With Real-World Evidence 3/30/2026

   Discover how how federated data networks, platform aggregators, and collaborative partnerships have evolved to meet the data demands of modern product development, regulatory strategy, and commercial success.

10. Bayesian Digital Twins Show Potential For Predicting Prognosis And Treatment Response 3/30/2026

    Learn how Bayesian digital twins are trained, validated, and trusted in clinical settings and explore the potential for integrating these models into interventional trials.